Background
==========

*Bacillus thuringiensis* (Bt) has been sold commericially and used as a biopesticide worldwide for over half a century. However, growing public concern surrounding Bt use has sparked worldwide debate over current policies \[[@B1]\]. For example, in India, fear over a potential *Bombyx mori* (silkworm) epizootic, or microbial pathogen outbreak, inspired a governmental ban on the use of Bt, despite the nation\'s continuing use of traditional chemical pesticides \[[@B2]\].

While pest control with Cry toxins that possess low *B. mori* activity (*i.e*. Cry1Ac) is a viable solution in affected countries, it is worthwhile to investigate the specific molecular mechanisms that make Cry1Aa highly active. Early work took advantage of the fact that Cry1Aa, but not Cry1Ac, is toxic to *B. mori*. For example, Ge *et al.*\[[@B3]\] exchanged hypervariable regions between genes encoding the two toxins and localized the toxicity specifying region of Cry1Aa to residues 332--450 in domain II. A follow-up study demonstrated the toxicity specifying residues were involved in binding *B. mori* brush border membrane vesicles \[[@B4]\]. More specifically, alanine substitution or deletion of residues 365 to 371 removed nearly all toxicity and binding to *B. mori* BBMV \[[@B5]\].

Recently, research on *B. mori* has focused on purifying and cloning the midgut epithelial receptors targeted by Cry1Aa toxin. The first toxin-binding receptor purified from *B. mori* was a 120-kDa aminopeptidase N (APN), which appears around 110-kDa on SDS-PAGE gels when preparative conditions are used that cleave its glycosyl-phosphatidylinositol (GPI) anchor. This receptor was shown to bind Cry1Aa with a 7.6 nM affinity, as determined by Scatchard analysis with ELISA binding assays \[[@B6]\]. The APN was cloned and expressed in *E. coli* and demonstrated to bind Cry1Aa toxin on ligand blots \[[@B7]\]. These results indicate the Cry1Aa-APN interaction was specific and that APN glycosylation was not required for Cry1Aa binding. This is not altogether surprising because Cry1Aa binding to *Manduca sexta* APN has not been found to be modulated by sugar binding \[[@B8]\] and the *B. mori* APN sequence is 73.7% identical to *M. sexta* APN-1. Sequence alignments with *Plutella xylostella* APN receptor indicate that a highly conserved region of APN likely functions as the toxin binding site \[[@B9]\]. By testing for toxin binding to lysylendopeptidase-digested *B. mori* APN fragments, the toxin binding site was suggested to be between Ile135 and Pro198. A later study by these authors identified 120-kDa and 115-kDa APNs coeluting from an anion-exchange column that together yielded a Cry1Aa affinity of 53 nM \[[@B10]\]. These APNs eluted just prior to a 120 kDa APN with 7.6 nM affinity. It is unclear whether the 120- and 115-kDa proteins represent uncleaved and cleaved GPI-anchor isozymes. Interestingly, this study also showed that Cry1Ac toxin binds to the 120/115 kDa APN fraction with equal affinity as Cry1Aa, and only 4-fold reduced affinity to the isolated 120-kDa APN. Nonetheless, Cry1Aa is 210 times more toxic than Cry1Ac to *B. mori*\[[@B4]\]. As a whole, *B. mori* APN research indicates the presence of at least three genetic isoforms \[[@B7],[@B11],[@B12]\], with toxin affinities ranging from nanomolar to none at all.

In addition to APN, a completely different toxin receptor class has been affinity precipitated by toxin from solubilized *B. mori* midgut proteins. In this manner, Nagamatsu *et al.*\[[@B13]\] purified a 175-kDa glycoprotein (BtR175) that bound Cry1Aa toxin. Interestingly, these authors did not observe binding of Cry1Aa to APN-sized bands in ligand blot studies with BBMV. Antibodies produced to BtR175 blocked toxin binding to the receptor in BBMV. The antibody serum also reduced Cry1Aa activity against *B. mori* when it was fed to larvae prior to toxin addition to the diet \[[@B14]\]. The same group cloned and introduced the BtR175 gene with a baculovirus vector into*Spodptera frugiperda* Sf9 cells. Addition of Cry1Aa caused swelling and lysis of only the Sf9 cells expressing BtR175. Based on sequence analysis, the receptor was characterized as a cadherin-like glycoprotein containing nine cadherin repeats, a membrane proximal region, one transmembrane region, and a small cytoplasmic domain \[[@B15]\]. Ihara *et al.*\[[@B16]\] also purified and partially sequenced what was presumed to be the same cadherin-like receptor. Binding studies indicated that the affinity of the cadherin for Cry1Aa is equivalent to that of the brush border membrane vesicles from *B. mori*\[[@B16]\], an affinity that is substantially lower than the APN affinities reported. Recently, cDNA variants of BtR175 have been discovered, showing at least three alleles of the cadherin-like receptor are found in *B. mori*\[[@B17]\]. It is likely that glycosylation plays a major role in cadherin-like receptor isoforms as well, as glycosylation has been observed previously for the *M. sexta* cadherin-like receptor BT-R~1~\[[@B18]\].

Progress in research on silkworm receptors for Bt toxins has provided a means for assaying mutant toxins with potentially altered binding and activity. In this study, we tested the hypothesis that Cry1Aa binds to both the 120-kDa *B. mori* APN and the 175-kDa *B. mori* cadherin-like protein. Based on the previous work of Ge, et al. \[[@B3]\] and Lee, et al. \[[@B4]\], we also postulated that domain II of Cry1Aa is the significant binding domain. These hypotheses were tested for the first time in studies with purified, native *B. mori* receptors (rather than BBMV) under real-time, non-labeled toxin binding conditions.

Results
=======

Bombyx mori aminopeptidase N and cadherin-like receptor purification
--------------------------------------------------------------------

To investigate the specificity of Cry toxins for *B. mori* receptors, the two known *B. mori* midgut receptors were purified from *B. mori* BBMV. Solubilized *B. mori* BBMV proteins were separated by Q Sepharose anion-exchange chromatography and all eluted fractions were tested for APN enzymatic activity. Additionally, Cry1Aa toxin binding capability was assayed by \"slot blotting\" all fractions and probing with biotin-Cry1Aa. The chromatogram in Fig. [1](#F1){ref-type="fig"} displays the separation of cadherin and APN from BBMV proteins. APN isozymes of 100- and 110-kDa were detected that did not show Cry1Aa-binding in slot blot assays (Fig. [1](#F1){ref-type="fig"}; fractions 24--25 and 30--31). Such isozymes have been reported previously \[[@B11],[@B12]\]. In addition, a 115-kDa APN was detected with Cry1Aa-binding capability (Fig. [1](#F1){ref-type="fig"}; fractions 33--36). As expected, fractions were also observed that exhibited no APN enzymatic activity but bound Cry1Aa on slot blots (Fig. [1](#F1){ref-type="fig"}; fractions 26--27). Initially these fractions were predicted to contain the cadherin-like Cry1Aa-binding protein \[[@B13],[@B14],[@B16]\]. The candidate receptor fractions for APN and cadherin were separately loaded on a size-exclusion column for further purification (Fig. [2A](#F2){ref-type="fig"} and [2B](#F2){ref-type="fig"}). A protein with APN enzymatic activity eluted 75 minutes after injection (Fig. [2A](#F2){ref-type="fig"}; fractions 15--16), approximately 4 minutes after the 120-kDa *L. dispar* APN elutes on the same column \[[@B19]\]. The candidate cadherin-like receptor fraction eluted in fractions 9--11 at around 180 kDa (Fig. [2B](#F2){ref-type="fig"}).

![Separation of *Bombyx mori* aminopeptidase N and cadherin-like receptor from solubilized BBMV proteins by anion-exchange chromatography. (A) The absorbance units at 280 nm (AU~280~) are indicated at left. At right, the percent of buffer B (% NaCl) and actual salt conductivity (% cond) of line traces are shown. Colored fractions denote: yellow, fractions with APN enzymatic activity, but without Cry1Aa-binding ability (24--25 and 30--31); green, fractions with both APN enzymatic activity and Cry1Aa-binding ability (33--36); and blue, fractions that have Cry1Aa binding but no APN activity (26--27).](1471-2091-2-12-1){#F1}

![(A) Further purification of anion-exchange purified *B. mori* APN (115 kDa) fractions (33--36) by size-exclusion chromatography. Absorbance (mAU) at 280 and 260 nm is shown at left. Collected fractions are shown at bottom in 5 ml intervals and run volume (ml) is indicated. Purified APN fractions used for further analysis are noted (15--16). (B) Purification of anion-exchange purified *B. mori* cadherin-like receptor (BtR175, 175 kDa) fractions (26--27) by size-exclusion chromatography. Absorbance at 280 nm is shown at left (mAU) Absorbance at 260 nm was insignificant (not shown). Purified BtR175 fractions used for further analysis are noted (9--11).](1471-2091-2-12-2){#F2}

Analysis of receptor purity
---------------------------

The pooled and concentrated candidate receptor fractions were examined by SDS-PAGE before and after size-exclusion purification to assess purity (Fig. [3](#F3){ref-type="fig"}). The putative cadherin-like receptor material appears at a molecular size around 180 kDa, both before and after secondary purification (Lanes 2 and 1, respectively). Several BBMV proteins appear present in the APN-containing fraction prior to size-exclusion purification (Fig. [3](#F3){ref-type="fig"}; Lane 4). The molecular weight of the final, purified APN was estimated to be 115--120 kDa (Fig. [3](#F3){ref-type="fig"}; Lane 3). It is not known whether the GPI anchor is still intact on the APN receptor; however, in the current study, phosphatidylinositol-specific phospholipase C (PIPLC) was not used during BBMV preparation. It was shown previously that APN may be purified with intact GPI-anchors if PIPLC is omitted from the preparation buffer \[[@B6]\]. It is likely that our APN has similarly retained the GPI anchor.

![SDS-PAGE (10%) of pooled and concentrated column-purified fractions. Molecular weights of marker bands (M) are at left. Lane 1, purified BtR175 from size-exclusion fractions 9--11 (Fig. [2B](#F2){ref-type="fig"}); Lane 2, anion-exchange column fractions 26--27 (Fig. [1](#F1){ref-type="fig"}) used for size-exclusion purification of BtR175; Lane 3, purified APN from size-exclusion fractions 15--16 (Fig. [2A](#F2){ref-type="fig"}); Lane 4, anion-exchange column fractions 33--36 (Fig. [1](#F1){ref-type="fig"}) used for size-exclusion purification of APN.](1471-2091-2-12-3){#F3}

In view of the fact that *B. mori* BtR175 possesses sequence similarity to *M. sexta* BT-R~1~, the candidate fraction was probed on a slot blot with anti-BT-R~1~ polyclonal antiserum. A weak to moderate cross-reactivity with anti-BT-R~1~ was observed for *B. mori* BBMV as well as the putative cadherin-like receptor fraction, providing strong evidence that the material is a cadherin-like protein (Fig. [4](#F4){ref-type="fig"}). Anti-Bt-R~1~ antibody recognition was not observed for fractions eluting before and after the cadherin material, nor for the purified APN (Fig. [4](#F4){ref-type="fig"}). Similar antibody assays were not performed to substantiate the identity of the purified APN because it clearly displayed strong, characteristic APN enzyme activity.

![*B. mori* cadherin-like receptor cross-reacts with anti-*M. sexta* BT-R~1~. All samples were slot blotted and probed with rabbit anti-BT-R~1~ antibody, followed by peroxidase-conjugated goat anti-rabbit antibody and development. *M. sexta* and *B. mori* brush border membrane vesicles (BBMV) antibody reactivity is shown. Also displayed are pooled and concentration fractions 5--8, 9--11, and 14--16 from size-exclusion column purification of BtR175 (Fig. [2B](#F2){ref-type="fig"}) and the purified APN from size-exclusion fractions 15--16 (Fig. [2A](#F2){ref-type="fig"}).](1471-2091-2-12-4){#F4}

The purity of both receptors was further examined by a Cry1Aa toxin ligand blot (Fig. [5](#F5){ref-type="fig"}). Both APN and the cadherin-like receptor fractions bound biotinylated Cry1Aa. No other toxin-binding bands were apparent, and neither purified receptor sample was visibly cross-contaminated with the other receptor (Fig. [5](#F5){ref-type="fig"}).

![Ligand blot of purified *B. mori* APN and cadherin-like receptors (5 μg each lane, 6% SDS PAGE) probed with biotinylated Cry1Aa toxin (50 μg). M, pre-stained molecular weight standards; APN, purified *B. mori* APN; cad, purified cadherin-like receptor.](1471-2091-2-12-5){#F5}

Affinity estimation by surface plasmon resonance
------------------------------------------------

Cry toxin binding studies have been reported previously for*B. mori* that used BBMV assays or used purified receptors in ELISA assays or blots; however, no Cry toxin studies concerning *B. mori* have been published employing SPR analysis. The affinity of Cry1Aa binding to *B. mori* APN and *B. mori* cadherin receptors was evaluated by real-time kinetic analysis on a BIAcore 2000. Simple bimolecular binding of Cry1Aa was observed to both *B. mori* APN and cadherin (Fig. [6A](#F6){ref-type="fig"} and [6B](#F6){ref-type="fig"}). Toxin-receptor on-rates for association (*k*~a~), off-rates for dissociation (*k*~d~), and overall binding affinity (*k*~d~/*k*~a~, or *K*~D~) were calculated for toxin binding. The apparent rate constants for wild-type Cry1Aa and *B. mori* APN were *k*~a~ = 2.0 × 10^4^ M^-1^s^-1^ (+/- 1.3 × 10^2^), *k*~d~ = 1.5 × 10^-3^ s^-1^ (+/- 1 × 10^-5^), and *K*~D~ = 75 nM. To *B. mori* cadherin, significantly tighter affinities were obtained: *k*~a~ = 1.3 × 10^4^ M^-1^s^-1^ (+/- 6.1), *k*~d~ = 3.3 × 10^-5^ s^-1^ (+/- 1 × 10^-5^), *K*~D~ = 2.6 nM. This apparent off-rate clearly accounted for Cry1Aa\'s higher affinity for cadherin than for APN. The cadherin off-rate observed in this study could have significant consequences in vivo: slow toxin dissociation may enable protracted lingering near the brush border membrane surface, greatly facilitating toxic (domain I) insertion and subsequent pore formation. The overall affinity determined in the present study for Cry1Aa to BtR175 (2.6 nM) agrees well with the findings of Ihara *et al.*\[[@B16]\] by a different assay (0.8 nM).

![Real-time binding of Cry1Aa to *B. mori* APN and cadherin-like protein, BtR175. Representative BIAcore response curves for toxin injections at 200, 300, 500, and 1000 nM. Experimental curves (gray) are shown overlaid with fitted curves (black) obtained with the 1:1 Langmuir binding model. Response units (RU) are shown at left (1 RU = 1 pg/mm^2^ of protein bound). (A) Cry1Aa wt binding to *B. mori* APN. (B) Cry1Aa wt binding to *B. mori* BtR175.](1471-2091-2-12-6){#F6}

We also explored the specificity of Cry1Aa for the native *B. mori* receptors by comparing the binding response of Cry1Aa with the binding of Cry1Ab, Cry1Ac, and domain-switched toxin 4109 (Fig. [7A](#F7){ref-type="fig"} and [7B](#F7){ref-type="fig"}). Hybrid toxin 4109 is particular useful in this context, because it is comprised of domains I and II from Cry1Aa and domain III from Cry1Ac (Aa/Aa/Ac) \[[@B3]\]. Hybrid-toxin 4109 binding to both receptors was not noticeably different from Cry1Aa: for APN binding, *k*~a~ = 1.9 × 10^4^ M^-1^s^-1^ (+/- 1.4 × 10^2^), *k*~d~ = 1.5 × 10^-3^ s^-1^ (+/- 1.6 × 10^-5^), and *K*~D~ = 78 nM; for cadherin binding, *k*~a~ = 1.3 × 10^4^ M^-1^s^-1^ (+/- 2 × 10^2^), *k*~d~ = 3.34 × 10^-5^ s^-1^ (+/- 2 × 10^-5^), and *K*~D~ = 2.6 nM. In stark contrast, Cry1Ab and Cry1Ac showed no apparent binding to either receptor (Fig. [7A](#F7){ref-type="fig"} and [7B](#F7){ref-type="fig"}). These results are entirely consistent with the hypothesis that Cry1Aa domain II (alone) is essential for binding to both the APN and cadherin-like receptors as purified in the present study.

![Sensorgrams of Cry1A toxins and hybrid toxin binding to purified native *B. mori* receptors. SPR response units (RU) are at left. Shown are overlaid traces of Cry1Aa, Cry1Ab, Cry1Ac and hybrid toxin 4109, consisting of domains I and II from Cry1Aa and domain III from Cry1Ac (Aa/Aa/Ac). (A) Toxin injection (500 nM) over immobilized aminopeptidase-N (APN). (B) Injection (500 nM) over immobilized *B. mori* cadherin-like protein.](1471-2091-2-12-7){#F7}

Discussion
==========

The dissociation constants presented are the first determined for *B. mori* Cry receptors by the use of SPR technology. Additionally, the apparent affinity of Cry1Aa for the cadherin-like receptor is the highest observed affinity to date for Cry toxin binding to purified receptors using SPR. This finding emphasizes the important biological role that this receptor class plays for Bt toxins. Recently, using phage display technology, a scFv molecule with short sequence homology to *M. sexta* and *B. mori* cadherin-like receptors was shown to bind domain II of Cry1Aa, Cry1Ab, and Cry1Ac toxins \[[@B20]\]. In the present study, only Cry1Aa shows measurable binding to the purified, native cadherin-like receptor from *B. mori*. This finding may be the result of purification of a particular receptor variant with Cry1Aa specificity (e.g., one of potentially several glycosylated isoforms). Alternatively, it may reflect greater specificity of Cry1Aa domain II for neighboring residues on the *B. mori* cadherin-like receptor beyond the conserved Cry1A-toxin binding segment, which might be absent in smaller peptide sequences.

The apparent Cry1Aa affinity for purified APN measured in this study, 75 nM, is 10-fold higher than the value reported by Yaoi *et al.*\[[@B6]\] for purified 110-kDa APN using a separate technique (7.6 nM). In the aforementioned study, an ELISA assay was used to indirectly calculate affinity by incubating receptor-bound toxin with a peroxidase-conjugated anti-Cry1Aa antibody over 1.5 hours at 37°C. It is possible that the difference in binding constants reflects our condition of more direct receptor-binding measurement in \"real-time\", as well as the different binding buffers and temperature used.

Yaoi *et al.*\[[@B21]\] estimated the toxin-binding region of *B. mori* APN to be between Ile135 and Pro198 based on toxin blot overlays with protease-digested APN fragments. BLAST sequence alignments \[[@B22]\] yielded 81% identity and 96% similarity between this 63 residue stretch and the homologous region of *M. sexta* APN-1, which also binds Cry1Aa toxin (Jenkins, unpublished observation). Interestingly, in *L. dispar* APN-1, which does not bind Cry1Aa, the same stretch is only 37% identical and 56% similar (4% unaligned gaps). These results appear to support the findings of Yaoi *et al.*\[[@B21]\]. However, *Heliothis virescens* (tobacco budworm) APN is only 45% identical and 53% similar to *B. mori* APN, yet it binds Cry1Aa toxin with high affinity \[[@B23]\]. Moreover, sequence alignments with APN from *Lactobacillus*, *Streptococcus*, *Saccharomyces*, *Arabidopsis*, rat, pig, yeast, and human yielded more similarity than *H. virescens* APN to the putative Cry1Aa-binding region of *B. mori* APN. It is likely that as the X-ray crystal structures of APNs are solved, structural alignments of APNs will help resolve the specificity-determining regions more accurately. Additionally, structural information will aid in the rational construction of toxins with reduced binding for beneficial insects without losing activity to target pests. In this context a unique Cry1Aa binding epitope within domain II has been identified that, when mutated, results in specific reduction of toxicity to *B. mori* (You, et al., unpublished manuscript). The application of protein engineering to *B. thuringiensis* insecticidal proteins is entering a new era of tailoring pesticides with reduced activity to beneficial insects as well as increasing activity against pest insects \[[@B24]\].

Conclusions
===========

Domain II of Cry1Aa is both necessary and essential for tight binding to two *B. mori* midgut receptors, the cadherin-like and aminopeptidase N receptors, a finding that correlates with biological activity data. The Cry1Aa binding affinity, as well as the dissociation rate for the cadherin-like receptor, are the lowest measured using the surface plasmon resonance technique. The SPR method presented here may be useful for screening other Cry toxins or Cry toxin variants specifically engineered to reduce or eliminate specificity for receptors from this non-target insect.

Materials and methods
=====================

Mutant toxin construction and preliminary analysis
--------------------------------------------------

Hybrid toxin 4109 consisting of domains I and II of Cry1Aa and domain III of Cry1Ac was constructed as previously described \[[@B3]\]. Force-feeding bioassays on *B. mori* and BBMV binding assays were conducted as described \[[@B4]\]. Crystal proteins were solubilized and trypsinized, and active toxins were column purified as carried out previously \[[@B19]\].

Receptor purification
---------------------

*B. mori* midguts were dissected from 4^th^ or 5^th^ instar larvae and brush border membrane vesicles were prepared by the Wolfersberger method \[[@B25]\]. *B. mori* BBMV (10 mg in 10 ml) was solubilized in 5 mg/ml CHAPS zwitterionic detergent (Roche) overnight at 4^o^C with gentle rocking. Solubilized BBMV was centrifuged at 10,000 × g for 10 min and supernatant was concentrated to 2 ml by Amicon YM30 ultrafiltration. The sample was then loaded on a Q Sepharose HR 10/30 anion-exchange column. All column chromatography was carried out on an ÄKTA Explorer (Amersham Pharmacia Biotech). Low salt buffer (buffer A) consisted of 20 mM Tris, 5 mM MgCl, 0.4 mg/ml CHAPS, pH 8.6, and the high salt buffer used was buffer A containing 1 M NaCl. A step gradient of salt was used to elute BBMV proteins. All fractions were tested for APN enzymatic activity by the LpNA assay. Briefly, 390 μl of sample are mixed with 10 μl of 2 mM leucine-p-nitroanilide (containing a leucine-phenylalanine dipeptide). A yellow chromophoric change indicates aminopeptidase N activity, defined as the ability to cleave a neutral amino acid from the N-terminus of a polypeptide. Cry1Aa binding ability was also checked by slot blotting fractions to PVDF membrane and probing with biotinylated Cry1Aa \[[@B26]\]. Fractions with Cry1Aa-binding ability and APN enzymatic activity were concentrated to 2 ml volumes and loaded on a Superdex 200 size-exclusion column (120 ml bed volume) using Hepes-buffered saline (HBS; 10 mM Hepes, 150 mM NaCl, 3.4 mM EDTA, pH 7.4) as running buffer. Absorbance was monitored at 280 nm and 260 nm to judge protein purity of collected peaks relative to flow through. Fractions eluting around 115--120 kDa, the MW of APN, were collected and protease inhibitors were added after a final concentration. Anion-exchange fractions with Cry1Aa-binding ability but without APN enzymatic activity were also size-purifed, and fractions eluting around 175--250 kDa, the MW of BtR175, were collected and concentrated. Approximately 0.10 mg (in 0.25 ml) of cadherin-like receptor and 0.30 mg of APN (in 1 ml) were obtained.

Analysis of receptor purity
---------------------------

Candidate receptor fractions were analyzed by 10% SDS-PAGE (40 μl/lane) and stained with Coomassie brilliant blue. For slot blot assays, 5 μg of *M. sexta* or *B. mori* BBMVs and 40 μl of candidate receptor fractions were blotted onto PVDF membrane and assays was carried out as reported previously \[[@B27]\], except for using 1:1000 anti-Bt-R~1~ polyclonal antiserum. For ligand blot assays, samples separated by SDS-PAGE (9%) were transferred to PVDF overnight, blocked with 5% dried milk in TTBS (50 mM Tris-HCl, 150 mM NaCl, 0.05% Tween 20, pH 7.5). Samples were probed with 50 μg biotin-Cry1Aa and streptavidin-conjugated horseradish peroxidase for 1 hr each, with 45 min TTBS washes, and developed in DAB/Urea (BioRad).

Surface plasmon resonance with purified midgut receptors
--------------------------------------------------------

*B. mori* APN and cadherin were immobilized on a CM5 sensor chip by the amine-coupling method (Biacore AB). Receptors were diluted into ammonium acetate, pH 4.2 prior to immobilization. An HBS (pH 7.4) buffer flow rate of 50 μl/min was used for all injections. Randomized toxin concentrations varying from 100 nM to 1000 nM were injected (110 μl) over the receptor surfaces. Surfaces were regenerated with 6 μl pulses of 10 mM NaOH, 250 μM ethylene glycol, pH 11.0 at 100 μl/min. Signal responses from a blank flowcell containing ethanolamine as a blocking agent were subtracted from all response curves and data were fitted using BIAevaluation 3.0. The curves were fit to a simple 1:1 Langmuir binding model to obtain apparent rate constants (A + B ↔ AB).
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